We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Inflammation Test Developed Predicts Cardiovascular Disease

By LabMedica International staff writers
Posted on 03 Nov 2016
Chronic inflammation, a decline in immune responsiveness, and reduced cardiovascular function are all associated with aging, but the relationships among these phenomena remain unclear.

An assessment blending several measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar. More...
A blood test produces a single number that strongly predicts the development of the world’s most prevalent medical disorder: cardiovascular disease.

An international team of scientists led by those at Stanford University School of Medicine (Stanford, CA, USA) longitudinally profiled a total of 84 signaling conditions in 91 young and older adults and observed an age-related reduction in cytokine responsiveness within four immune cell lineages, most prominently T cells. Testing for levels of C-reactive protein (CRP), a circulating protein linked to inflammation, has been shown to further enhance the prediction of cardiovascular risk, even among patients with normal cholesterol levels. A CRP reading is relatively simple to get, requiring only a blood draw and relatively straightforward laboratory tests.

The new test developed is more complicated but appears to have superior diagnostic value to either the cholesterol or CRP test. Rather than testing circulating inflammatory proteins, it tests for the response of immune cells themselves to inflammation, a signal that appears to be more stable and hence a more robust diagnostic. In the study, it was able to detect early cardiovascular irregularities in otherwise asymptomatic individuals. The phenotype can be partially explained by elevated baseline levels of phosphorylated STAT (pSTAT) proteins and a different response capacity of naive versus memory T cell subsets to interleukin 6 (IL-6), interferon α (IFN-α), and, to a lesser extent, IL-21 and IFN-γ.

When immune cells from young people were stimulated with certain cytokines, the activation levels of STAT proteins skyrocketed. When the same thing was done to immune cells from old people, STAT-protein activity increased a lot less. The investigators blended 15 separate cytokine-responsiveness measurements to generate a single number called a cytokine response score (CRS). This measure, which varied considerably among different older adults, was quite stable from year to year for any given individual.

A higher CRS is better, as it indicates a more-responsive immune system and lower background inflammation. The team found that cytokine response scores were inversely correlated with clinical signs of atherosclerosis and with two measures associated with the heart’s ability to relax between beats. Importantly, the borderline subjects also had low cytokine response scores.

Mark M Davis, PhD, professor of microbiology and immunology and the senior author of the study, said, “For too many men experiencing a heart attack or stroke, the first observed hint of cardiovascular risk is their death. The CRS may be a useful proxy for healthy aging and its predictive accuracy in cardiovascular disease further substantiates the inflammatory underpinnings of that prevalent, age-related condition.” The study was published on October 13, 2016, in the Cell Systems.

Related Links:
Stanford University School of Medicine


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.